Principal Securities, Inc. Immunovant, Inc. Call Options Transaction History
Principal Securities, Inc.
- $4.14 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMVT
# of Institutions
212Shares Held
64.4MCall Options Held
697KPut Options Held
629K-
Vanguard Group Inc Valley Forge, PA6.51MShares$179 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.4MShares$93.4 Million1.17% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.88MShares$79.3 Million2.5% of portfolio
-
State Street Corp Boston, MA2.72MShares$74.8 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...